Sakarya Tıp Dergisi (Jun 2022)

How We Treated a Kidney Transplant Recipient Who Was Receiving Sirolimus During the SARS-CoV-2 Pandemic? Primum Non Nocere

  • Selcuk Yaylacı,
  • Hamad Dheir,
  • Savaş Sipahi,
  • Ahmed Bilal Genç,
  • Oğuz Karabay,
  • Necattin Fırat,
  • Mehmet Köroğlu,
  • Yasemin Gündüz,
  • Didar Şenocak

DOI
https://doi.org/10.31832/smj.783277
Journal volume & issue
Vol. 12, no. 2
pp. 345 – 348

Abstract

Read online

The new Coronavirus SARS-CoV-2 (COVID-19) epidemic continues to affect the world. It is emphasized that COVID-19 is more severe in patients with solid organ transplantation, and the risk of mortality may be higher than in the normal population. Herein, with the first time, we described a COVID-19 pneumoniae kidney recipient case treated with sirolimus. A 49-year-old male patient had kidney transplantation 13 years ago. He was used prednisolone and sirolimus. His main complaints were fever (38.3°C) and weakness. Atypical pneumoniae was diagnosed with thorax computed tomography. The respiratory specimen of the patient was positive with COVID-19 by PCR test. Sirolimus was stopped due to the immunosuppressive effect, and the treatment switched to low dose everolimus. Also, hydroxychloroquine, oseltamivir and azithromycin triple therapy was started for five days. The patient was discharged with healing on the seventh day.

Keywords